Tag Archives: Novartis

Civica Rx Finding Success in Supply Generic Drugs

Civica Rx’s mission is to ensure that essential generic medications are accessible and affordable

BMS Implementing Digital Therapeutics Strategy

BMS digital strategy has required thinking differently about the type of value-based relationships the company wants to establish

Startups Continue to Enter the Digital Clinical Trial Market

New digital technologies offer a centralized, standardized approach to capturing, analyzing and predicting patient behavior

Digital Therapeutics Market Continues to Experience Growing Pains

Investment in Digital Therapeutics is expanding rapidly with industry stakeholders working to develop their strategies for success

Prescription Digital Therapeutics Market On The Move

PDTs are being developed for a range of conditions, from schizophrenia and depression, to multiple sclerosis and Alzheimer’s, to oncology and GI disorders, and more

Pear Therapeutics and Ironwood Pharmaceutical Evaluating GI Digital Therapeutics

Ironwood Pharmaceuticals testing digital therapeutics opportunity with Pear Therapeutics

Outcome-Based Contracting Acceptance Grows in Market

Specialty Pharma Services

Outcome-Based Contracting Acceptance Grows in market with the concept of taking on financial risk on complex contracts as a result of market pressure combined with more familiarity. Outcome-based contracts between pharma companies and health insurers are becoming increasingly popular. In 2016, Novartis, Amgen, and Sanofi publicized risk-sharing, value-based, outcomes-based, or pay-for-performance deals, all of which vary […]

Increasing Demand for Drug Based Outcomes

Specialty Pharma Services

Increasing Demand for Drug Based Outcomes – Outcome-based contracts are a relatively new and growing contracting methodology focused on shifting reimbursement from volume to value. The contracts are between a health plan and manufacturer where reimbursement is dependent on pre-defined outcome metrics focused on improving patient responses/health. Currently, the relationship between the pharmaceutical manufacturer, the […]